2026年11月4日星期三
M
Panorama Universal
Noticias globales
Nintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei Asia

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease

Fuente 柳叶刀 LancetHace 11 días
Resumen del contenido

Sickle cell disease is the most common haemoglobinopathy, affecting more than 7 million people worldwide.1 Despite substantial morbidity and mortality, access…

Este sitio solo proporciona títulos e índices de resúmenes; el contenido completo y los derechos de autor pertenecen al publicador original. Haga clic en el enlace original para leerlo.

Ir al texto original
Canal al que pertenece
Salud
Región a la que pertenece
Reino Unido
Idioma original
English
Número de entrada
health-7abf72c7

Comments 0 comments

No comments yet. Be the first.

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease · Panorama Universal